TY - JOUR
T1 - Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma
AU - Lin, Pei
AU - Dickason, Timothy J.
AU - Fayad, Luis E.
AU - Lennon, Patrick A.
AU - Hu, Peter
AU - Garcia, Mar
AU - Routbort, Mark J.
AU - Miranda, Roberto
AU - Wang, Xumei
AU - Qiao, Wei
AU - Medeiros, L. Jeffrey
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2012/3/15
Y1 - 2012/3/15
N2 - BACKGROUND: B-cell lymphoma, Unclassifiable with features intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma, for convenience referred to here as unclassifiable B-cell lymphoma, is a category in the 2008 World Health Organization system used for a group of histologically aggressive neoplasms that are difficult to classify definitively. Currently, there is no established standard therapy for these neoplasms. METHODS: The authors assessed MYC status and correlated it with treatment response and outcome in a group of 52 patients with unclassifiable B-cell lymphoma treated with either a standard DLBCL regimen (R-CHOP [rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone-related therapy]) or more intensive regimens, such as R-hyper-CVAD (rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine). The regimens were selected by the treating clinicians based on the overall clinical and pathological findings. RESULTS: Thirty (58%) unclassifiable B-cell lymphomas had MYC abnormalities (MYC +) including 27 with rearrangement, 2 with amplification, and 1 with both. The MYC + and MYC - groups were similar in their age distribution and International Prognostic Index scores. Progression-free survival of patients with MYC + unclassifiable B-cell lymphoma treated initially with R-CHOP was significantly worse than patients treated with R-hyper-CVAD (P =.0358). In contrast, for the MYC - unclassifiable B-cell lymphoma group, some patients responded to R-CHOP, and others were refractory to R-hyper-CVAD. CONCLUSIONS: MYC aberrations are common in unclassifiable B-cell lymphoma. The presence of MYC aberrations identifies a patient subset that requires more aggressive therapy than R-CHOP. In contrast, MYC - unclassifiable B-cell lymphoma patients responded variably to either R-CHOP or aggressive therapy, and the latter showed no survival advantage.
AB - BACKGROUND: B-cell lymphoma, Unclassifiable with features intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma, for convenience referred to here as unclassifiable B-cell lymphoma, is a category in the 2008 World Health Organization system used for a group of histologically aggressive neoplasms that are difficult to classify definitively. Currently, there is no established standard therapy for these neoplasms. METHODS: The authors assessed MYC status and correlated it with treatment response and outcome in a group of 52 patients with unclassifiable B-cell lymphoma treated with either a standard DLBCL regimen (R-CHOP [rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone-related therapy]) or more intensive regimens, such as R-hyper-CVAD (rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine). The regimens were selected by the treating clinicians based on the overall clinical and pathological findings. RESULTS: Thirty (58%) unclassifiable B-cell lymphomas had MYC abnormalities (MYC +) including 27 with rearrangement, 2 with amplification, and 1 with both. The MYC + and MYC - groups were similar in their age distribution and International Prognostic Index scores. Progression-free survival of patients with MYC + unclassifiable B-cell lymphoma treated initially with R-CHOP was significantly worse than patients treated with R-hyper-CVAD (P =.0358). In contrast, for the MYC - unclassifiable B-cell lymphoma group, some patients responded to R-CHOP, and others were refractory to R-hyper-CVAD. CONCLUSIONS: MYC aberrations are common in unclassifiable B-cell lymphoma. The presence of MYC aberrations identifies a patient subset that requires more aggressive therapy than R-CHOP. In contrast, MYC - unclassifiable B-cell lymphoma patients responded variably to either R-CHOP or aggressive therapy, and the latter showed no survival advantage.
KW - Burkitt lymphoma
KW - MYC
KW - diffuse large B-cell lymphoma
KW - gray zone lymphoma
KW - high-grade B-cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=84863230289&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863230289&partnerID=8YFLogxK
U2 - 10.1002/cncr.26433
DO - 10.1002/cncr.26433
M3 - Article
C2 - 21882178
AN - SCOPUS:84863230289
SN - 0008-543X
VL - 118
SP - 1566
EP - 1573
JO - Cancer
JF - Cancer
IS - 6
ER -